Belgium will deliver 153,900 vaccines to Uganda. These vaccines will contribute to stepping up the vaccination campaign for teachers and reopening schools to more than 10 million pupils and students. With this, Belgium is responding to the Ugandan government's request to receive COVID-19 vaccines.
On August 2, the Ugandan government addressed an official request for assistance from the EU Civil Protection Mechanism to the Emergency Response Coordination Center (ERCC). The request for assistance consisted of administering the second dose of AstraZeneca to vaccinate the 162,026 teachers who received the first dose and 100,000 doses from Johnson&Johnson to vaccinate rural teachers for whom the logistics of vaccination will be facilitated with a single-dose vaccine.
The 153,900 doses of AstraZeneca vaccines arrived in Kampala on Wednesday, September 22 at 10:20 pm. This vaccine donation is supported by the Embassy of Belgium in Kampala and Enabel - the Belgian Development Agency, in charge of logistics and coordination with the Ugandan authorities.
“Every child back to school. Everywhere in the world. That's my goal. By vaccinating teachers we contribute to providing renewed access to education for as many children, youngsters and students in Uganda, as quickly as possible" emphasises Minister of Development Cooperation, Meryame Kitir."
According to Ugandan authorities, vaccinating priority groups such as teachers will help reopen schools for more than 10 million pupils and students. Uganda has experienced a new wave of COVID-19 in recent months, with a daily peak of 2,280 cases per day in June 2021 and a confirmed mortality spike in July (up to 40 per day). On September 17 it was noted that vaccination coverage remains very low overall: approximately 1,622,367 people (out of a population of approximately 45 million) received at least one dose of a vaccine. The availability of the COVID-19 vaccine in Uganda remains minimal and below the African average. To control the pandemic, the country has had to take drastic measures, resulting in the complete closure of schools for almost 18 months.
The impact on students (primary and secondary) has been particularly severe. Young people have not been to school for 18 months; distance learning is hardly possible due to the lack of equipment and internet connection.
In addition to this bilateral donation to Uganda, our country will redirect 4 million doses to third countries by the end of this year. Belgium is mainly using the COVAX mechanism for this purpose.
At the request of the Minister of Development Cooperation, Meryame Kitir, our country's focus for the next deliveries will be on Africa and more specifically on our African partner countries, where access to vaccines is sorely lacking. Only 2% of Africa's total population has been vaccinated. "We can be very proud of the high vaccination coverage in our country. But at the same time, I remain very concerned because many people in vulnerable countries do not have access to a vaccine. This virus has no borders. International solidarity and cooperation is the only way out of this health crisis. We will only be safe when everyone is safe," said Minister Kitir.
To date, two million doses of vaccine have been allocated by Belgium for vaccine sharing. Almost one million doses have already been delivered to third countries, of which more than 70% are African countries.
Distributed by APO Group on behalf of Kingdom of Belgium - Foreign Affairs, Foreign Trade and Development Cooperation.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
